.Pharmacolibrary.Drugs.ATC.A.A16AB13 .Pharmacolibrary.Drugs.ATC.A.A16AB13| name: | AsfotaseAlfa |
| ATC code: | A16AB13 | route: | subcutaneous |
| n-compartments | 1 |
Asfotase alfa is a recombinant human tissue-nonspecific alkaline phosphatase enzyme replacement therapy indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP), a rare genetic disorder characterized by defective bone mineralization due to deficient activity of alkaline phosphatase. It is an approved medication for this indication.
Pharmacokinetics in pediatric and adult patients with hypophosphatasia, based on population PK studies and summary data from clinical trials.
Pan, WJ, et al., & Seefried, L (2021). Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia. Journal of clinical pharmacology 61(10) 1334–1343. DOI:10.1002/jcph.1870 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33822385